Clinical trial
Nevanac 3-Month Safety Study With QID Dosing
NCT00332774 · Alcon Research, Industry · Completed
Key facts
| NCT number | NCT00332774 |
|---|---|
| Title | Nevanac 3-Month Safety Study With QID Dosing |
| Official title | A 3-Month Clinical Safety Comparison of Nevanac 0.1% to Acular LS 0.4% and Vehicle Following Cataract Surgery |
| Lead sponsor | Alcon Research, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Cataract |
| Intervention type | Drug, Other |
| Interventions | Nepafenac ophthalmic solution 0.1%, Ketorolac Tromethamine ophthalmic solution 0.4%, Nepafenac ophthalmic suspension vehicle |
| Enrollment | 149 |
| Start date | Feb 1, 2006 |
| Primary completion | Dec 1, 2006 |
| Completion | Dec 1, 2006 |
| First posted | Jun 2, 2006 |
| Last update posted | Mar 5, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: